Reports Outline Liposomes Study Findings from Capital Medical University (Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/II Clinical Trial).

A recent study conducted at Capital Medical University in Beijing, China, explored the combination of Mitoxantrone Hydrochloride Liposome (PLM60) with Tislelizumab in patients with relapsed or refractory NK/T cell lymphoma. The study aimed to assess the safety and efficacy of this combination therapy. The results showed that PLM60 plus Tislelizumab demonstrated promising efficacy with manageable safety profiles in patients with relapsed or refractory NK/T cell lymphoma. Further research is needed to determine long-term outcomes such as progression-free survival and overall survival. [Extracted from the article]